

September 15, 2020

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

Scrip code: 532531

The National Stock Exchange of India Limited

Exchange Plaza , Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051

Scrip code: STAR

Dear Sirs,

Sub: Intimation regarding request received for issue of duplicate share certificate under Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

We would like to inform that the Company has received request for issue of duplicate share certificate from the following shareholders who have lost their original share certificates.

#	Folio No.	Name of the Shareholders	Certificate No.	Distinctive Nos.	No. of shares
1	SAL006993	Manoj Kumar Agarwal/ Suman Devi Agarwal	51873 and 51874	13456110-13456121	12

The Company/ Registrar and Transfer Agent (RTA) is in the process of reviewing the request. Duplicate share certificate shall be issued only on receipt of complete documents from the shareholder to the satisfaction of the RTA and the Company including completion of procedural requirements in this regard.

We have also enclosed the email request received from the shareholder for your ready reference.

This is for your information and records.

Thanks and Regards,

For **Strides Pharma Science Limited**



Manjula Ramamurthy
Company Secretary



Encl: a/a

From: Phani Kumar Meka <phani.meka@kfintech.com>

Sent: 11 September 2020 21:00

To: Kala Raghunath <Kala.R@strides.com>

Cc: S V Raju <raju.sv@kfintech.com>; A Mohan Kumar <mohan.a@kfintech.com>; K Ramesh Babu <ramesh.kabothu@kfintech.com>

Subject: issue of duplicate share certificate _SAL006993_ MANOJ KUMAR AGARWAL/ SUMAN DEVI AGARWAL

CAUTION: This email has originated from outside of the organization. Do not click links or open attachments unless you recog

Dear Madam,

The below email received from investor for loss of share certificate and the share certificates are not in postal returns.

Details are given below...

S.no	Name	Folio no	Shares	Certificate No		Distinctive No	
				From	To	From	To
1	MANOJ KUMAR AGARWAL/ SUMAN DEVI AGARWAL	SAL006993	12	51873	51874	13456110	13456121

Regards

Phani Kumar M
Corporate Registry



KFin Technologies Private Limited

=====
=====
From : Manoj Agarwal (manoj.agarwal8701@gmail.com)

To : inward.ris@kfintech.com

Subject : Fwd: Shares & dividend

Date : 10/09/2020 16:09

Attachments :

----- Forwarded message -----

From: **Manoj Agarwal** <manoj.agarwal8701@gmail.com>

Date: Thu, Sep 10, 2020, 5:30 PM

Subject: Shares & dividend

To: <inwaed.ris@kfintech.com>

Folio sal 002274

Suman devi agarwal 25shars

Folio sal006794

Manoj Kumar agarwal 12 shares

Folio sal006993

Suman devi agarwal 12 shares

Ye three folio ka dividend sp & shares nahi mele he so ky karna he

This message and its attachments (if any) is intended only for the use of the individual or entity to which it is addressed. It may contain information or data that is confidential, privileged, non-public and proprietary in nature which is duly protected under law. Any unauthorised use and/or dissemination of the information or data shall entitle us to take necessary legal action. If you are not the intended recipient of this email, you are requested to, (a) immediately delete it and confirm back to us, and (b) abstain from using and/or disseminating the information or data any further.

Disclaimer:

The information contained in this communication is intended solely for the use of the individual or entity to whom it is addressed and others authorized to receive it. This communication or any attachment hereto may contain Unpublished Price Sensitive Information (UPSI) or confidential or legally privileged information. You shall ensure that based on any UPSI of the Company that you may have had access to during the course of your business with the Company, you and your employees shall not make any trade in the shares of the Company. You are required to maintain confidentiality of any UPSI that you may have had access to in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

If you are not the intended recipient, any disclosure, copying, distribution or action taken relying on the contents is prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by responding to this email and then delete it from your system. No liability is accepted for any harm that may be caused to your systems or data by this message.

Unless related to Company business, the opinions, conclusions and other information contained within this email are those of the sender alone and do not necessarily constitute those of Strides Pharma Science Limited. Strides Pharma Science Limited reserves the right to monitor emails sent to or from addresses under its control.

This message and its attachments (if any) is intended only for the use of the individual or entity to which it is addressed. It may contain information or data that is confidential, privileged, non-public and proprietary in nature which is duly protected under law. Any unauthorised use and/or dissemination of the information or data shall entitle us to take necessary legal action. If you are not the intended recipient of this email, you are requested to, (a) immediately delete it and confirm back to us, and (b) abstain from using and/or disseminating the information or data any further.